Skip to main content
COVID-19

Medical Policy Revision: Homocysteine Testing in the Screening, Diagnosis, and Management of Cardiovascular Diseases

Effective January 4, 2015, Horizon Blue Cross Blue Shield of New Jersey will change the way we consider certain claims for the use of homocysteine testing in the diagnosis and treatment of cardiovascular diseases.

According to the guidelines of our medical policy, Homocysteine Testing in the Screening, Diagnosis, and Management of Cardiovascular Diseases, measurement of plasma levels of homocysteine is considered investigational in the screening, evaluation and management of members who have cardiovascular disease.

Based on the guidelines included in our revised medical policy, Homocysteine Testing in the Screening, Diagnosis and Management of Cardiovascular Diseases AND the submitted diagnosis or diagnoses code(s), CPT® code 83090 submitted on claims for services provided on and after January 4, 2015 may be denied as an investigational service.

Review this revised policy in our online Medical Policy Manual.

Unless Horizon BCBSNJ gives written notice that all or part of the above changes have been cancelled or postponed, the changes will be applied to claims for dates of service on and after January 4, 2015.

CPT® is a registered mark of the American Medical Association.

Published on: October 2, 2015, 12:41 p.m. ET
Last updated on: November 24, 2020, 23:44 p.m. ET